Leveraging over 30 years of senior leadership experience in the healthcare sector, Mr. Potenza is the President & CEO of Strategyn Management Group (SMG), a Texas based, privately held “HealthTech” consulting firm. SMG provides early to mid-phase providers, and emerging technology developers, the senior management experience, organizational resources, market intelligence and access to capital markets needed for rapid growth, market adoption and possible acquisition.
Prior to heading his own firm, Mr. Potenza resigned from a combined 11-year carrier as Vice President of Healthcare Economics at Kimberly Clark Healthcare (KCH), and an incombent position as Zone Vice President of I-Flow Corp, which was acquired by KCH in a highly profitable transaction. Mr. Potenza also enjoyed 10-yrs of senior business development/leadership position(s) at Baxter Healthcare and served as Senior/Executive Vice President at three early and mid-phase start-ups that would be acquired in private transactions. All total, Mr. Potenza has been involved in over $1-billion in equity buy-out transactions.
Mr. Potenza did his under-graduate studies at Ithaca College in upstate NY, where he studied Business Management, played Div III football, and completed course work at Cornell University. He completed his post-graduate executive education studies at Southern Methodist University's Cox School of Business and the Wharton School of Business at the University of Pennsylvania. He is certified in Six-Sigma and LEAN, a student of Deming (CQI), is married and a father of two boys, and contributes his time and resources by sitting on several corporate, charity and community boards and organizations.
Dr. Gombrich has approximately 20 years of development experience in the In Vitro diagnostic sector, namely around infectious disease and cancer testing. Dr. Gombrich was instrumental in market development of several rapid diagnostic assays for pneumonia-related pathogens, including the Binax (Alere) Rapid Legionella Assay and Pneumococcal Urinary Antigen tests. This included post-market clinical study design and the creation of sales and marketing educational content.
Dr. Gombrich also has been involved in product development of a point-of-care cervical cancer screening test aimed at the developing world. Dr. Gombrich received his Medical Degree and Masters degree in Experimental Pathology from Case Western Reserve University in Cleveland in 2005. He was previously Chief Medical Officer of Vivione Biosciences, Inc. and was instrumental in the commercialization of several pulmonary disease related assays.
Mr. Ramsaroop is a senior research scientist at Aperture Bio, where he designs, develops and validates new microbiological detection assays. Shawn has previously served in the United States Air Force as a Space System Operator and has an additional 11 years’ experience with developing new flow cytometric assays in industries such as food safety, oil & gas, and clinical microbiology.
He has co-authored several white papers and other publications with various respectable public and private industries, as well as developed assay and platform that have been approved by such organizations as the Association of Official Analytical Chemists (AOAC) and the USDA Food Safety and Inspection Service (FSIS).
Mrs.Benson has more than 30 years’ experience in Medical Device Quality Assurance. Her expertise includes Quality System Regulation 21 CFR 820, ISO 13485 and MDD requirements. Ms. Benson has a Quality Assurance Compliance consulting business for the last 15 years.
In addition, she has held positions at companies such as Affymetrix, Sangstat Medical and Mast Immunosystems. Ms. Benson received her B.S. in Agriculture from the University of Vermont.
Dr. Keys has consulted for over 2 dozen companies over the past 20 years including Affymetrix, Beckman-Coulter, Eurogentec, Orasure, and T2 Biosystems. With his Chemistry and IVD background, he assists clients evaluate technology, improve processes, establish design controls and quality systems, develop/launch strategy and plan organizational development and growth.
Dr. Keyes was previously Vice-President of Product Development at Osmetech (now Genmark) where he oversaw facility build-out, staffing, and product development leading to ISO13485 certification in 2008. During his tenure he directed R&D and Operations collaborations across 3-Osmetech sites leading to solving pervasive oligo labeling yield and quality issues, developing new CMO relationships, and enabling the launch of a second IVD platform.
As an Associate Director at bioMeriéux’ Rockland, MA location, he led exploratory molecular IVD commercialization efforts for Chlamydia, GC and MTb tests on a modified VIDAS immunoassay platform in collaboration with Gen-Probe. He began his career at Roche Diagnostics, where he rose to Section Manager at Roche Molecular Systems, directing 4-teams in the R&D and launch of 2 new PCR infectious disease IVD test systems and has 5-publications
in peer reviewed journals.
Dr. Keyes earned his B.S. in Chemistry from Western New England College, his Ph.D. in Organic Chemistry from The Pennsylvania State University and held a post-doctoral research appointment at the University of Chicago, Department of Chemistry.